Inventors:
Neel K. Anand - Burlingame CA, US
Charles M. Blazey - San Francisco CA, US
Owen Joseph Bowles - Pacifica CA, US
Joerg Bussenius - Foster City CA, US
Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Baili Chen - Palo Alto CA, US
Erick Wang Co - San Diego CA, US
Simona Costanzo - Los Altos CA, US
Steven Charles Defina - Burlingame CA, US
Larisa Dubenko - San Francisco CA, US
Maurizio Franzini - San Francisco CA, US
Ping Huang - Mountain View CA, US
Vasu Jammalamadaka - Pleasonton CA, US
Richard George Khoury - Redwood City CA, US
Moon Hwan Kim - Palo Alto CA, US
Rhett Ronald Klein - Chicago IL, US
Donna Tra Le - San Jose CA, US
Morrison B. Mac - San Francisco CA, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Kenneth D. Rice - San Rafael CA, US
Tsze H. Tsang - El Cerrito CA, US
Amy Lew Tsuhako - Milpitas CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Assignee:
Exelixis, Inc. - South San Francisco CA
International Classification:
A61K 31/501
A61K 31/497
C07D 473/16
C07D 401/04
US Classification:
51425202, 51425216, 544277, 544238, 544363
Abstract:
The present invention relates to compounds of the Formula (I) and (II) wherein R, R, R-R, m, n, X-X, and Qare defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.